Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics (Nasdaq: AKRO), a clinical-stage company developing treatments for serious metabolic diseases, announced it will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET in New York. The presentation will be available via live webcast on the company's investor relations webpage, with an archived replay accessible afterward.
- Presentation at a major healthcare conference can increase visibility and investor interest.
- Webcast availability allows broader access to the presentation, enhancing transparency.
- The press release lacks specific new business developments or clinical data updates.
- No financial data or significant milestones are mentioned, which might disappoint some investors looking for concrete progress.
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:00 p.m. E.T. in New York, NY.
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as two ongoing Phase 3 clinical trials: the SYNCHRONY Histology study in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study in patients with MASH (F1-F3 fibrosis) or MASLD. A third clinical trial, the SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4 fibrosis), is expected to be initiated in the second quarter of 2024. The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco. Visit us at akerotx.com and follow us on LinkedIn and X for more information.
Investor Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
Media Contact:
Sarah O’Connell
732.456.0092
soconnell@vergescientific.com
FAQ
When will Akero Therapeutics present at the Jefferies Global Healthcare Conference?
How can I view Akero Therapeutics' presentation at the Jefferies Global Healthcare Conference?
Will there be a replay of Akero Therapeutics' presentation at the Jefferies Global Healthcare Conference?
What is the stock symbol for Akero Therapeutics?
